Showing results (1171-1180 of 1,395) with videos related to

Sort By:
Pageof 140
Journal of Medical Genetics|July 25, 1998
Identification of a common low density lipoprotein receptor mutation (C163Y) in the west of ScotlandW K Lee, L Haddad, M J Macleod, et al.
Human Pathology|March 26, 2005
Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in TaiwanWun-Ju Shieh, Cheng-Hsiang Hsiao, Christopher D Paddock, et al.
Science (New York, N.Y.)|September 12, 1986
High Nitrite Levels off Northern Peru: A Signal of Instability in the Marine Denitrification RateL A Codispoti, G E Friederich, T T Packard, et al.
Neuroscience|June 1, 2018
Palatable Food Affects HPA Axis Responsivity and Forebrain Neurocircuitry in an Estrous Cycle-specific Manner in Female RatsAnn E Egan, Abigail M K Thompson, Dana Buesing, et al.
JAMA|November 12, 2009
Major lipids, apolipoproteins, and risk of vascular disease, Emanuele Di Angelantonio, Nadeem Sarwar, et al.
Plos Medicine|January 27, 2009
Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysisIan Ford, Vladimir Bezlyak, David J Stott, et al.
Journal of Internal Medicine|December 18, 2019
Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjectsE Björnson, C J Packard, M Adiels, et al.
Antioxidants & Redox Signaling|October 18, 2017
Ultrafine Particle Exposure Reveals the Importance of FOXO1/Notch Activation Complex for Vascular RegenerationKyung In Baek, René R Sevag Packard, Jeffrey J Hsu, et al.
Diabetes, Obesity & Metabolism|April 12, 2019
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemiaMartin Adiels, Marja-Riitta Taskinen, Elias Björnson, et al.
Atherosclerosis|January 26, 2021
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trialAntonio J Vallejo-Vaz, Chris J Packard, Brian A Ference, et al.
Pageof 140